Novartis' Gleevec indicates potential to treat Alzheimer's

09/1/2010 | Reuters

U.S. researchers found that Novartis' cancer drug Gleevec has the ability to block the beta-amyloid protein that triggers development of brain-damaging plaques in mice with Alzheimer's disease. "The development of compounds that work like Gleevec, but have the ability to pass the blood-brain barrier and target gamma-secretase activating protein could revolutionize the treatment of this disease," the lead researcher said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Associate Manager, Regulatory Affairs
Stryker
Mahwah, NJ
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC